KROS vs PH · rev $3.5M vs P/E 28, rev $19.85B
Keros Therapeutics Inc (KROS) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported KROS revenue for 2024-12-31 was $3.5M. Net income was -$187.4M. Revenue was up 2251.0% from 2023-12-31 to 2024-12-31. KROS currently screens at market cap $208.8M.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
KROS currently screens at market cap $208.8M. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the KROS and PH stock pages for the full models.
Not investment advice.